洛铂联合氟尿嘧啶和甲酰四氢叶酸治疗晚期耐药胃癌 结直肠癌疗效观察

Clinical Observation of Lobaplatin plus 5-Fu and Leucovorin in Treatment of Refractory Advanced Gastric and Colorectal Cancer

目的:观察新一代铂类化疗药洛铂联合氟尿嘧啶(5-Fu)/甲酰四氢叶酸(CF)治疗晚期耐药胃癌、结直肠癌的疗效。方法:31例晚期耐药胃癌、结直肠癌患者全部使用洛铂与甲酰四氢叶酸钙(CF)与氟尿嘧啶(5-Fu)联合化疗的方案治疗。结果:完全缓解(CR)1例,占3.2%,部分缓解(PR)6例,占19.4%,稳定(SD)14例,占45.2%,进展(PD)10例,占32.3%。总有效率(ORR)22.6%(7/31)。Ⅰ～Ⅳ度不良反应发生率以疲倦最高,占48.4%,贫血占41.9%,厌食占38.7%,白细胞下降占35.5%,恶心呕吐占32.3%,血小板下降占22.6%,ALT升高占16.1%,除疲倦外,均为轻到中度。结论:洛铂是一种安全、有效的第三代铂类抗肿瘤新药,临床中可尝试应用于既往方案化疗失败的胃癌、结直肠癌患者。

Objective： To observe curative effect of Lobaplatin plus 5-Fu/CF, the new antitumor platinum drugs, on advanced gastric or colorectal cancer. Methods： Thirty-one patients with advanced gastric or colorectal cancer were treated using the Lobaplatin/CF/5-Fu regimen. Results： The complete response （CR）, partial response （PR）, stable disease （SD） and progressive disease （PD） rates were 3.2% （1/31）, 19.4% （6/31）, 45.2% （14/31） and 32.3% （10/31） respectively, with an overall response rate （CR＋ PR） of 22.6% （7/31）. The toxic effect was slight. Languor was the most common symptom in the grade-Ⅰ to Ⅳ adverse reactions, accounting for 48.4% of the total cases. Other related symptoms included the anaemia （41.9%）, anorexia （38.7%）, leukocytopenia （35.5%）, vomiting and nausea （32.3%）, thrombocytopenia （22.6%） and increase of ALT （16.1%）. Conclusion： Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect, and it can try to be use on the patients who have received chemotherapy which conclude 5-Fu.